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Chyawanprash (Chy) is an ayurvedic formulation commonly consumed in Indian households. Chy is a comprehensive herbal
tonic, prepared from around 50 herbs employing anwala (Emblica oﬃcinalis) as the basic ingredient. The present study was
undertaken to explore the beneﬁcial eﬀects of Chy (at the dose of 1 and 2% w/w of diet) administered daily for 15 successive days
in mice with memory deﬁcits. A total of 228 mice divided in 38 groups were employed in this study. Morris water maze, Hebb-
Williams maze and elevated plus maze served as exteroceptive memory models, whereas scopolamine (Sco)-induced amnesia
and alprazolam (Alp)-induced amnesia served as interoceptive memory models. The brain acetylcholinesterase activity, brain
thiobarbituric acid reactive substances (TBARS) and reduced glutathionelevels (GSH) were also estimated. The administration of
Chy for 15 consecutive days signiﬁcantly protected the animals from developing memory impairment. Furthermore, there was a
signiﬁcantdecreaseinbrainTBARS andincreaseinGSHlevelsafteradministrationofChy(2%w/w),thereby indicatingdecreased
free radical generation and increased scavenging of free radical, respectively. Thus, Chy may prove to be a useful remedy for the
managementof Alzheimer’s disease owing to its antioxidant eﬀect, pro-cholinergic action and/or antiamnesic potential.
1.Introduction
Learning and memory are two fundamental cognitive func-
tionsthatconferustheabilitytoaccumulateknowledgefrom
our experiences [1]. Learning refers to the acquisition of any
new information aboutthe eventsoccurring in surroundings
and subsequent retrieval of this information is referred to as
memory [2]. Memory is one of the most complex functions
of the brain and ultimately involves multiple neuronal path-
ways and neurotransmitters. Impairment of memory is an
organic brain disorder deﬁned as “loss of intellectual ability
of suﬃcient severity to interfere either with occupational
functioning, usual social activities or relationship of a person
in the absence of gross clouding of consciousness or motor
involvement” [3]. Decreased cholinergic ﬁring in brain
[4], rise in oxidative stress [5], hypercholesterolemia [6],
neuroinﬂammatory reactions [7] have been demonstrated
to play an etiological role in memory decline. Since the
allopathic system of medicine has yet to provide a radical
cure for memory impairment, it is worthwhile to look for
new directions, which would minimize the memory loss of
patients with neuropsychiatric disorders.
Chyawanprash (Chy), a household remedy all overIndia,
is popular for its nutritional value. In ayurveda, Chy is clas-
siﬁed under the category of Rasayana, which aims at main-
taining physique,vigor and vitality,while delayingthe ageing
process [8, 9]. It has been relished in India as a health
food since ancient times with the same enthusiasm for the
past 4000 years. Chy had been one of the most respected
anti-ageing ayurvedic tonic, long before the clinical impor-
tance of vitamins, minerals and antioxidants was appreciated
[8].
Chyisacomplexmixtureofmorethan50herbalingredi-
ents. All the ingredients in Chy have been scientiﬁcally stud-
ied individually for their health beneﬁts. The combination
of these nutrients used in Chy in a speciﬁc quantity and
manner of blending creates a powerful synergy for optimum
health beneﬁts. Chy is helpful in clearing the accumulated
excretabypromotingdigestionandexcretion[8,10].Itisnot
only hepatoprotective but it also streamlines the metabolism2 Evidence-Based Complementary and Alternative Medicine
Table 1: Proportion of constituents of Chy.
Common name Plant name
Weight per
100g of
Chy
Dashmool
Aegle marmelos Corr.
3.98g
Desmodium bulbifera Desv.
Gmelina arborea Roxb.
Oroxylum indicum Vent.
Premna integrifolia Linn.
Solanum indicum Linn.
Solanum xanthocarpum Schard.
Stereospermum suoveolens DC
Tribulus terrestris Linn.
Uraria picta Desv.
Bala Sida cordifolia Linn 0.398g
Mudgaparni Phaseolus tribolus-sensu Ait 0.398g
Mashparni Teramnus labialis Spreng 0.398g
Karkatshringi Pistacia integerima Stew-ex Brandis 0.398g
Bhumiamlaki Phyllanthus niruri Linn. 0.398g
Jivanti Leptadenia reticulata Wight & Am 0.398g
Pushkarmool Inula racemosa Hook. 0.398g
Agarkashta Aquillaria agallocha Roxb. 0.398g
Haritaki Terminalia chebula Retz. 0.398g
Guruchi Tinospora cordifolia Meirs 0.398g
Katchur Curcuma zedoaria Rosc 0.398g
Mustak Cyperus rotundus Linn 0.398g
Punarnava Boerhaavia diﬀusa Linn 0.398g
Neelkamal Nelumbium speciosum Willd 0.398g
Vasaka Adhatoda vasica Nees. 0.398g
Kakanasa Martynia diandra Glox 0.398g
Yashtimadhu Glycyrrhiza glabra Linn 0.398g
Varahikand Dioscorea bulbifera Linn 0.796g
Ashwagandha Withania somnifera Dunal 0.796g
Satavari Asparagus racemosus Willd 0.796g
Vidarikand Ipomoea digitata Linn 1.195g
Anwala green Emblica oﬃcinalis Gaertn 90g
Ghrit Milk fat 2.08g
Sesame oil Sesamum indicum Linn 1.20g
Banslochan Bambusa arundinacea Willd 0.8g
Akarkara Spilanthes acmella Linn 0.126g
Pippali Piper longum Linn. 1.12g
Nagkesar Mesua ferrea Linn. 0.116g
Dalchini Cinnamomum zeylanicum Breyn 0.116g
Tejpatra Cinnamomum tamala Nees & Ebrm 0.116g
Lavang Eugenia caryophyllus Linn 0.128g
Elaichi Elettaria cardamomum Maton 0.588g
Kesar Crocus sativus Linn. 0.021g
Chandansaar Ptertocarpus santalinus Linn 0.0092g
Abhrak Bhasam Ayurvedic preparation 0.188g
Muktasukti
Pishti Ayurvedic preparation 0.063g
Silver foil — q.s.
Sugar — q.s.
q.s.: quantity suﬃcient.
of fats and proteins [11, 12]. It relieves cough, asthma, bron-
chospasm, respiratory tract infections and tuberculosis [13].
It possesses promising antioxidant, cardiotonic, cholesterol
lowering and anti-inﬂammatory properties [8, 10, 14, 15].
Chy is made in anwala base (Indian gooseberry, Emblica
oﬃcinalis)[ 16],which isone oftherichest sources of vitamin
C (ascorbic acid) [17]. Anwala as well as ascorbic acid has
been shown to be eﬀective as memory enhancers in our
earlier studies [18–20]. On similar lines, all formulations
in which anwala or ascorbic acid are used as a base
(or principal constituent) would produce beneﬁcial eﬀects
on memory performance by virtue of their ascorbic acid
content. Furthermore, no scientiﬁc data are available on the
usefulness of Chy in the management of dementia till date to
the best of our knowledge. In the light of above, the present
study was undertaken toexplore the antiamnesic potential of
Chy.
2.Methods
2.1. Chy. Chy manufactured by Dabur, India was used in
the present study. The proportion of various constituents
of Chy is given in Table 1. Chy was administered orally for
15 successive days in two diﬀerent doses (1 and 2% w/w)
by admixing with the standard diet. The doses of Chy were
determinedonthebasisofapilotstudyandliteraturereports
[8, 10, 14]. The animals were given the food ad libitum.T h e
diet intake was measured daily by weighing the remaining
diet (uneaten)inthecagesand subtracting thisamount from
the total feed amount given on the previous day.
2.2. Drugs. The drugs and chemicals employed in this study
were obtained from following drug houses: Chy (Dabur,
India), donepezil hydrochloride (Donep; Wokhardt Ltd.,
Baddi, India), alprazolam (Alp) ( I n d - S w i f t ,B a d d i ,I n d i a ) ,
Sco hydrobromide (Sigma Aldrich, USA), 1,1,3,3-tertra-
methoxy propane (Sigma Aldrich, USA), 5,5-dithiobis-2-
nitrobenzoic acid (DTNB) and reduced glutathione (Sisco
Research Laboratories Pvt. Ltd., Mumbai, India), Piracetam
(Nootropil, UCB India Ltd, India), acetylcholine iodide,
eserine salicylate, sodium dihydrogen phosphate, disodium
hydrogen phosphate (Hi-Media, India). Sco HBr and Donep
HCl were dissolved in distilled water. Alp was suspended in
1% carboxymetylcellulose sodium.
2.3. Animals. Swiss male mice (20–25g, 3-4 months of age)
were employed in this study, as consequent variation in
estrogen levels in female mice may inﬂuence the cognitive
behavior of the animals [21]. All the animals were procured
from the disease-free small animal house of CCS Haryana
Agriculture University, Hisar, Haryana, India. The animals
had free access to food and water. They were subjected to
a natural light-dark (12h each) cycle. The animals were
acclimatized for at least 5 days to the laboratory conditions
prior to behavioral experiments. Experiments were carried
out between 09:00 and 18:00h. The experimental protocol
was approved by the Institutional Animal Ethics Committee
and the care of the laboratory animals was taken as per the
guidelinesofCPCSEA,Ministry ofForestsandEnvironment,
Government of India.Evidence-Based Complementary and Alternative Medicine 3
2.4. Laboratory Models for Testing Memory
(1) Exteroceptive behavioral models, such as (i) Mor-
ris water maze (MWM), (ii) Hebb-Williams maze
(HWM) and (iii) elevated plus maze (EPM), and
(2) Interoceptive behavioral models, such as (i) Sco-
inducedamnesia (1.4mg kg−1;i.p.) [22] and (ii)Alp-
inducedamnesia (0.5mgkg−1;i.p.)wereemployedin
the present study [23, 24].
2.5. MWM. The procedure, technique and end point for
testing memory were followed as per the parameters
described earlier [23, 24]. Brieﬂy, MWM consisted of a
circular pool (150cmin diameter, 45cm in height) ﬁlled to a
depth of 30 cm with water maintained at 25◦C. The water
was made opaque with non-toxic white colored dye. The
tank was divided into four equal quadrants with the help of
two threads, ﬁxed at right angle to each other on the rim of
the pool. A submerged platform (10cm2), painted in white
was placed inside the target quadrants (Q4 in present study)
of this pool 1cm below surface of water. The position of
platformwas keptunaltered throughout the training session.
Each animal was subjected to four consecutive trials each
day with a gap of 5min for four consecutive days (starting
from 15th day of Chy administration to 18th day), during
which they were allowed to escape on to the hidden platform
and to remain there for 20s. If the mouse failed to ﬁnd the
platformwithin 120s, it was guidedgently onto the platform
and allowed to remain there for 20s. Escape latency time
(ELT) was deﬁned as the time taken by the animal to locate
the hidden platform. ELT was noted as an index of learning.
On ﬁfth day (i.e., 19th day of Chy administration), the
platform was removed. Mouse was placed in water maze
and allowed to explore the maze for 120s. Each mouse
was subjected to four such trials and each trial was started
from a diﬀerent quadrant. Mean time spent in all the three
quadrants, that is, Q1, Q2 and Q3 was recorded and the time
spent in the target quadrant (TSTQ) in search of the missing
platform provided as an index of retrieval. Care was taken
nottodisturbtherelativelocationofwatermaze with respect
to other objects in the laboratory.
2.6. HWM. HWM is an incentive-based exteroceptive
behavioral model useful for measuring spatial working
memory of rodents. The procedure, techniqueand end point
for testing memory were followed as per the parameters
described earlier in our studies [23, 25]. Brieﬂy, HWM
consists of mainly three components, (i) animal chamber (or
start box), which is attached to (ii) the middle chamber (or
exploratory area) and (iii) a reward chamber at the other
end of the maze in which reward (food) is kept. All the
three components were provided with guillotine removable
doors. Onthe ﬁrst day (i.e.,15th day of Chy administration),
the mouse was placed in the animal chamber and the door
was opened to facilitate the entry of animal into the next
chamber. The door of the start box was closed immediately
after the animal moved into the next chamber so as to
preventbackentry. Time takenbytheanimal toreach reward
chamber (TRC) from start box on 1st day reﬂected the
learning index. Each animal was allowed to explore the maze
for3min with all thedoorsopenedbefore returning tohome
cage. Retention (memory score) of this learned task was
examined 24h after the ﬁrst-day trial. Signiﬁcant reduction
in TRC value indicated improvement of memory.
2.7.EPM. EPM servedastheexteroceptivebehavioral model
to evaluate short-term memory in mice. The procedure,
technique and end point for testing memory was followed as
per the parameters described earlier [23, 26]. Brieﬂy, EPM
for mice consisted of two open arms (16cm × 5cm) and
two covered arms (16cm × 5cm× 12cm) extended from a
central platform (5cm × 5cm), and the maze was elevated
to a height of 25cm from the ﬂoor. On the ﬁrst day (i.e.,
15th day of Chy administration), each mouse was placed
at the end of an open arm, facing away from the central
platform. Transfer latency (TL) was deﬁned as the time (in
seconds) taken by the animal to move from the open arm
into one of the covered arms with all its four legs. The
mouse was allowed to explore the maze for another 2min
and then returned to its home cage.Retention of this learned
task (memory) was examined 24h after the learning trial.
Signiﬁcant reduction in TL value indicated improvement of
memory.
2.8. Measurement ofLocomotorActivity. The eﬀectofChy on
ambulation (spontaneous locomotor activity) was recorded
using Medicraft photoactometer (INCO, Ambala, India) in
diﬀerent groups of mice.
2.9. Experimental Design. Mice were divided in 38 groups
comprising of six animals in each group. Chy was admin-
istered for 15 days. After completion of 15 days, behavioral
studies were carried out using MWM (Groups I–XII),HWM
(Groups XIII–XXIV) and EPM (Groups XXV–XXXVI). Chy
administration was continued during maze studies, that is,
Chy was administered for 16 days in case of EPM and HWM
and for 19 days in case of MWM. The animals had free
accesstofoodandwaterbeforesubjectingthemtobehavioral
studies using mazes. Piracetam is an established memory
enhancer [14, 27] available in market, it served as positive
control to compare the memory enhancing activity of Chy in
all the exteroceptive behavioral models.
Groups I, XIII, and XXV (control groups): Standard diet
(without Chy) was administered to mice.
Groups II and III, XIV and XV and XXVI and XXVII
(Chy groups): Chy in two concentrations (1 and 2% w/w
in the diet) was administered to mice daily for 15 successive
days.
Groups IV, XVI, and XXVIII (piracetam groups): Pirac-
etam (400mg kg−1; i.p.) was administered for 15 successive
days to mice.
GroupsV,XVII,andXXIX(Scogroup):Sco(1.4mgkg−1;
i.p.) was administered daily from (days 1 to 4) 30min before
training on water maze.
Groups VI and VII, XVIII and XIX and XXX and XXXI
(Chy + Sco groups): Chy in two concentrations (1 and 2%4 Evidence-Based Complementary and Alternative Medicine
w/w in the diet) was administered to mice daily for 15
successive days. Sco (1.4mg kg−1; i.p.) was injected after
90min of Chy administration daily from days 15 to 18.
Groups VIII, XX, and XXXII (Piracetam + Sco group):
Piracetam (400mg kg−1; i.p.) was administered for 15 suc-
cessive days to mice. Sco (1.4mg kg−1; i.p.) was injected after
90min of piracetam administration daily from days 15 to 18.
Groups IX, XXI and XXXIII (Alp group): Alp (0.5mg
kg−1; i.p.) was administered daily from (days 1 to 4) 30min
before training on water maze.
Groups X and XI, XXII and XXIIIand XXXIVand XXXV
(Chy + Alp groups): Chy in two concentrations (1 and 2%
w/w in the diet) was administered to mice daily for 15 suc-
cessive days. Alp (0.5mgkg−1; i.p.) was injected after 90min
of Chy administration daily from days 15 to 18.
Groups XII, XXIV and XXXVI (Piracetam + Alp group):
Piracetam(400mgkg−1;i.p.)wasadministeredfor15succes-
sive days to mice. Alprazoalm (0.5mgkg−1; i.p.) was injected
after 90min of piracetam administration daily from days 15
to 18.
After behavioral studies, animals were sacriﬁced by
decapitation. The whole brain was removed, weighed and
homogenized in an ice bath after adding 10 volumes of
phosphate buﬀer(pH 7.4). The homogenate was centrifuged
at 3000rpm for 15min and the resultant cloudy supernatant
ﬂuid was used forestimation ofacetylcholinesterase (AChE),
reduced glutathione (GSH) and thiobarbituric acid reactive
substances (TBARS).Since Donep is a marketed preparation
for the management of Alzheimer’s disease (AD), which acts
through inhibition of acetyl-cholinesterase enzyme [3, 28],
it served as a standard drug for conﬁrming AChE inhibitory
activity of Chy. Furthermore, Donep has also been reported
to possess antioxidant activity [3, 28], it served as a standard
drug for comparing TBARS and GSH levels.
Group XXXVII (Donep group): Donep (0.1mg kg−1;
i.p.) was administered for 15 days daily to mice. Estimation
ofbrain AChE,GSH and TBARSwas carried out on 15th day
after 90min of Donep administration.
Group XXXVIII (Donep + Sco group): Donep (0.1mg
kg−1; i.p.) was administered for 15 days daily to mice. Sco
(1.4mg kg−1; i.p.) was injected on 15th day after 90min
of Donep administration. Estimation of brain AChE, GSH
and TBARS was carried out on 15th day after 45min of Sco
administration.
2.10. Estimation of Brain AChE Levels. The whole brain
AChE activity was measured by the method of Ellman et al.
withaslightmodiﬁcation[29,30].Thec hangeinabs orbanc e
per minute of the sample was recorded spectrophotometri-
cally at 420nm.
2.11. Estimation of Brain GSH Levels. The whole brain GSH
level was measured by the method of Beutler et al. [31]. The
absorbancewasmeasured spectrophotometrically at412nm.
2.12. Estimation of Brain TBARS Levels. The whole brain
TBARS level was measured by the method of Ohkawa et al.
[32]. The absorbance was measured spectrophotometrically
at 532nm.
2.13. Statistical Analysis. All the results were expressed as
mean ± SEM. Data were analyzed using one way analysis of
variance followed by post hoc Tukey’smultiple range test. P <
.05 was considered to be statistically signiﬁcant.
3.Results
The administration of Chy has not aﬀected the diet intake
and weight of the animals in comparison to control group
animals in the present study.
3.1. Chy Prevented Development of Memory Deﬁcits. The
administration of Sco (1.4mg kg−1; i.p.) and Alp (0.5mg
kg−1; i.p.) before training trials induced amnesia in mice
using MWM (Table 2). Furthermore, Sco and Alp adminis-
tration to mice signiﬁcantly increased both TRC (Figure 1)
and TL (Figure 2) when recorded using HWM and EPM,
respectively. These observations suggested that Sco and Alp
had produced impairment in learning as well as mem-
ory. However, Chy alone did not produce any signiﬁcant
improvement in memory scores of mice in these behavioral
models (Figures 1 and 2]. But, Sco and Alp induced
memory deﬁcits were successfully reversed by Chy (1 and
2% w/w) as indicated by decreased day 4 ELT, increased
day 5 TSTQ (Table 2), decreased TRC (Figure 1)a n d
decreasedTL(Figure 2).Piracetam(400mgkg−1;i.p.)served
as the positive control and pretreatment with piracetam
reversed Sco- and Alp-induced memory deﬁcits as expected
(P < .05).
3.2. Brain AChE Activity. No statistically signiﬁcant diﬀer-
ences were observed in brain AChE activity of Chy-treated
mice and control group mice. On the other hand, adminis-
tration of Sco (1.4mg kg−1, i.p.) signiﬁcantly increased the
brain AChE activity, which was reversed (P < .05) by Chy
administered chronically for 15 days. Donep (0.1mg kg−1;
i.p.) used as a standard drug, showed decrease in brain AChE
activity of mice as expected (Figure 3).
3.3. Antioxidant Studies. No statistically signiﬁcant diﬀer-
ences were observed in TBARS levels (Figure 4)a n dG S H
levels (Figure 5) in mice treated with Chy (1% w/w). But,
Chy (2% w/w) signiﬁcantly diminished (P < .05) brain
TBARS levels and enhanced brain GSH levels as com-
pared to the control group. Administration of Sco (1.4mg
kg−1; i.p.) not only increased the brain TBARS levels but
decreased brain GSH levels, when compared to control
group (P < .05). Administration of both Chy and Donep
signiﬁcantly reversed the Sco-induced increase in brain
TBARS levels (Figure 4)a n dd e c r e a s ei nb r a i nG S Hl e v e l s
(Figure 5).
In the present study, Alp did not aﬀect signiﬁcantly the
brain AChE activity, TBARS levels and GSH levels in any
manner. Chy (1 and 2% w/w in the diet) when administered
for 15 successive days did not show any signiﬁcant changeEvidence-Based Complementary and Alternative Medicine 5
Table 2: Eﬀect of Chy on day 4 ELT and day 5 time spent in target quadrant (TSTQ) of mice using MWM.
Group Treatment Dose Day 1 ELT (s) Day 4 ELT (s) Day 5 TSTQ (s)
I Control (normal) Standard diet 69.7 ± 2.4 25.6 ± 1.8a 73.4 ± 3.6
II Chy 1% w/w, in diet 68.6 ± 1.6 24.2 ± 2.4 70.6 ± 4.2
III Chy 2% w/w, in diet 65.6 ± 0.6 26.7 ± 2.9 72.8 ± 2.4
IV Piracetam 400mg kg−1; i.p. 67.9 ± 3.9 13.4 ± 3.1b 89.9 ± 2.2e
VS c o 1 . 4 m g k g −1; i.p. 66.3 ± 3.5 56.2 ± 3.6b 29.2 ± 4.9e
VI Chy + Sco 1% w/w, in diet + 1.4mg kg−1; i.p. 64.3 ± 1.2 34.8 ± 2.1c 52.1 ± 1.8f
V I I C h y+S c o 2 %w / w ,i nd i e t+1 . 4m gk g −1; i.p. 62.1 ± 4.3 25.4 ± 1.3c 61.2 ± 4.6f
VIII Piracetam + Sco 400mg kg−1;i . p .+1 . 4m gk g −1; i.p. 62.3 ± 2.9 14.4 ± 2.7c 66.3 ± 2.8f
IX Alp 0.5mg kg−1; i.p. 63.4 ± 2.9 59.9 ± 4.3b 24.3 ± 1.2e
X C h y+A l p 1 %w / w ,i nd i e t+0 . 5m gk g −1; i.p. 63.7 ± 2.7 32.1 ± 1.6d 54.2 ± 3.2g
XI Chy + Alp 2% w/w, in diet + 0.5mg kg−1; i.p. 60.1 ± 2.5 22.1 ± 4.1d 64.6 ± 3.7g
XII Piracetam + Alp 400mg kg−1;i . p .+0 . 5m gk g −1; i.p. 66.3 ± 1.9 17.3 ± 2.3d 69.1 ± 3.6g
Piracetam (400 mg kg−1; i.p.) is used as a standard drug. Values are mean ± SEM.
aP < . 0 5a sc o m p a r e dt od a y1E L Ti nc o n t r o l .
bP < . 0 5a sc o m p a r e dt od a y4E L Ti nc o n t r o l .
cP < . 0 5a sc o m p a r e dw i t hd a y4E L Ti nS c og r o u p .
dP < . 0 5a sc o m p a r e dw i t hd a y4E L Ti nA l pg r o u p .
eP < .05 as compared to day 5 TSTQ in control.
fP < . 0 5a sc o m p a r e dw i t hd a y5T S T Qi nS c og r o u p .
gP < . 0 5a sc o m p a r e dw i t hd a y5T S T Qi nA l pg r o u p .
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Figure 1: Eﬀect of Chy administered for 15 successive days on
time taken by mice to reach reward chamber (TRC) using HWM.
Piracetam (Pira) (400mg kg−1; i.p.) is used as a standard drug.
Values are mean ± SEM; aP < .05 as compared to control group;
bP < .05 as compared with Sco group; cP < .05 as compared with
Alp group.
in locomotor activity of mice (scores: 193 ± 12 and 202
± 14) as compared to control animals (score: 178 ± 09).
The schematic diagram illustrating the beneﬁcial eﬀect of
Chy on memory is depicted in Figure 6.
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Figure 2: Eﬀect of Chy administered for 15 successive days on TL
of mice using EPM. Piracetam (Pira) (400mg kg−1; i.p.) is used as
a standard drug. Values are mean ± SEM; aP < .05 as compared to
control group; bP < .05 as compared with Sco group; cP < .05 as
compared with Alp group.
4.Discussion
Dementia is a clinical syndrome characterized by the devel-
opment of multiple cognitive defects that are severe enough
to interfere with daily social and professional functioning6 Evidence-Based Complementary and Alternative Medicine
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Figure 4:Eﬀect ofChy administered for15 successive daysonbrain
TBARS. Donep (0.1mg kg−1;i.p.) is used asa standarddrug. Values
are mean ± SEM; aP < .05 as compared to control group; bP < .05
as compared with Sco group.
[33]. AD is the most common cause of dementia in the
elderly, accounting for 60–70% of all demented cases. AD-
related dementias are neurodegenerative conditions char-
acterized by progressive brain dysfunction occurring in a
step-wise biologicsequence:neuronalinjury; synaptic failure
and neuronaldeath.Neuroﬁbrillary tangles, amyloid plaques
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Figure 5:Eﬀect ofChy administered for15successive daysonbrain
GSH level. Donep (0.1mg kg−1; i.p.) is used as a standard drug.
Values are mean ± SEM; aP < .05 as compared to control group;
bP < .05 as compared with Sco group.
Memory
agent eg.
scopolamline
Chyawanprash
Increased
oxidative stress
Cellular dysfunction
of neurons
Competitively block
muscarinic
Decreased cholinergic
transmission
Memory
impairment
Increased
AChE activity
impairment
Figure 6:Schematicdiagramillustratingthebeneﬁcialeﬀect ofChy
on memory.
and degeneration ofcholinergic neuronsare thepathological
hallmarks of AD [34]. To improve cholinergic transmission,
diﬀerent strategies are adopted, including increase of ACh
synthesis, the augmentation of presynaptic ACh release, and
the stimulation of cholinergicp o s ts y n a p t i cm u s c a r i n i ca n d
nicotinic receptorsandthe inhibitionofAChsynaptic degra-
dation by employing cholinesterase inhibitors [35]. Despite
the availability of various treatment strategies, the severity
and prevalence of this disease are not yet under control.
Therefore, alternative and complementarymedicines includ-
ing herbalsupplementsarebeing utilizedinthemanagement
of this disease [18, 36].Evidence-Based Complementary and Alternative Medicine 7
In the present study, Sco and Alp produced amnesia in
experimental animals as indicated by the increased day 4
ELT, reduced TSTQ (time spent to reach target quadrant)
using MWM, increased TL using EPM and increased TRC
(time taken to reach reward chamber) using HWM. Sco
(centrally acting anti-muscarinic drug) and Alp (a benzo-
diazepine) have been extensively utilized to induce memory
deﬁcits in experimental animals [37, 38]. Alp and other
benzodiazepines produce amnesia in laboratory animals by
activationofbenzodiazepinereceptors[39,40].Pretreatment
withChyorallyfor15successivedayspreventedmemory loss
of mice as reﬂected by the decreased day 4 ELT, increased
TSTQ using MWM, reduced TL using EPM and decreased
TRC using HWM as compared to respective control animals.
In the present study, it was observed that Chy failed to
improve memory of normal animals. Alp-induced memory
deﬁcitsweresuccessfullyreversedbyChy,whenadministered
for 15 consecutive days. These ﬁndings suggest that Chy may
be serving as a protective agent in some manner which was
successful in preventing the damage elicited by Alp.
Sco-induced amnesia is mediated through blockade of
central muscarinic receptors [24]. Since Chy reversed Sco-
induced amnesia in the present study, it appears that Chy
might have produced either competitive displacement of Sco
from cholinergic (muscarinic) receptors or stimulated in
somemanner thesynthesis ofacetylcholine.The antiamnesic
eﬀe c to fC h ym a yb ed u et ot h ep r e s e n c eo fa n w a l a( E.
oﬃcinalis) in abundant quantity. This suggestion is con-
ﬁrmed by ourearlier studieswhere an ayurvedicformulation
comprising principally of Anwala Churna produced a dose-
dependent improvement in memory scores and reduction
in brain cholinesterase activity of young and aged mice
[14, 20]. Anwala is the one of the richest source of Vitamin
C[ 17]. Parle and Dhingra [19] had shown vitamin C
(ascorbic acid) to be a promising memory enhancer. In
this study, ascorbic acid administered for 8 consecutive days
not only improved learning and memory in aged mice but
also protected young mice from Sco and diazepam induced
impairment of memory. On similar lines, all formulations
in which anwala (or ascorbic acid) is used as a base (or
principal constituent) would produce beneﬁcial eﬀects on
memoryperformancebyvirtueofascorbicacidcontent.This
also explains the underlying mechanism of Chy which has
reversed the memory deﬁcits induced by Sco and Alp.
An increased lipid peroxidation due to increased genera-
tion of free radicals and decreased scavenging of free radicals
duetoreducedantioxidantenzymeshasbeenreportedinAD
brain [41, 42]. Sco signiﬁcantly increased the oxidative stress
as indicated by the increased TBARS and decreased GSH
levels in the present study. This observation is supported by
several reports in literature [22, 43, 44]. The administration
of Chy for 15 successive days to mice not only decreased
oxidative stress but also prevented the Sco-induced rise in
oxidative damage as indicated by the reduced TBARS and
increased GSH levels as compared to respective control
animals. Emblica oﬃcinalis [17], Withania somnifera [45],
Nelumbium speciosum [46], Sesamum indicum [47], Cin-
namomumtamala[48],Vitisvinifera [49],Piperlongum[50],
Sida cordifolia [51], Terminalia chebula [52], Aegle marmelos,
Ipomoea digitata, Phyllanthus niruri, Tinospora cordifolia and
Boerhaavia diﬀusa [53] are individually reported to possess
antioxidant activity. Therefore, it seems likely that Chy may
prove to be a useful antioxidant by virtue of its inhibitory
eﬀect on free radical generation and stimulatory eﬀect on
scavenging of free radicals. In the present study, Alp did not
aﬀect signiﬁcantly the brain AChE, TBARS and GSH levels
in any manner probably because the mechanism of action of
AlpisrelatedtobenzodiazepinereceptorsandGABAactivity.
It is noteworthy that phytoconstituents such as E. oﬃc-
inalis [17]a n dW. somnifera [45] present in Chy have been
reported to be potent antioxidants. The phytoconstituents
such as Eugenia caryophyllus [54]a n dV. vinifera [55] possess
potent anticholinesterase activity (pro-cholinergic action),
which may be responsible for the nootropic eﬀect of Chy.
In addition, W. somnifera [56], T. cordifolia [57], E. oﬃcinalis
[20]andP. longum [58]are alsoreported toimprove memory
and memory deﬁcits. In the light of above discussion, it may
be concluded that Chy induced antiamnesic eﬀect may be
related to its pro-cholinergic and/or antioxidant activities.
However, further investigations focused on potential eﬀects
of Chy on speciﬁc genes (by gene-expression analyses
especially in the hippocampus) and other neurotransmitters
involved in reversing memory defects are essential.
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